Please note – you will leave a website owned by MacroGenics, Inc.
MacroGenics is not responsible for any content on the third party website.
As a biopharmaceutical company, our team of 240+ dedicated individuals is focused on discovering and developing innovative antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. Our core scientific expertise is in the field of protein engineering and all of our product candidates have been created through our proprietary protein engineering platforms, including our proprietary Fc Optimization and Dual-Affinity Re-Targeting, or DART platforms. These platforms are generally focused on the creation of antibodies, antibody derivatives, and antibody-like molecules for use as therapeutic agents. Our products and platforms have attracted multiple partnerships with leading pharmaceutical and biotechnology companies around the globe.
We currently have a pipeline of product candidates in human clinical testing, primarily against different types of cancers. These include two product candidates developed using our proprietary Fc Optimization platform, namely margetuximab, an antibody that we are evaluating in a Phase 3 clinical trial in patients with metastatic breast cancers and enoblituzumab, an antibody that we believe has the potential for broad impact across a variety of different tumor types through multiple potential mechanisms of action. In addition, we have created a number of product candidates based on our proprietary DART platform and several of these are currently in human clinical development.